Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
V33q0Z34Q4pvaxYR
Listen
